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FLUDARABINE, CYCLOPHOSPHAMIDE WITH OR WITHOUT LOW DOSE
TBI FOR ALTERNATIVE DONOR TRANSPLANTS IN ACQUIRED APLASTIC
ANEMIA (SAA): A REPORT FROM THE EBMT-SAA WORKING PARTY
Bacigalupo, A., Locatelli, F., Lanino, E., Marsh, J., Socie, G., Passweg, J.
Ospedale San MArtino, Genova, Italy
We have previously reported the outcome of 38 acquired SAA pa-
tients allografted from alternative donor transplants after conditioning
withfludarabine30mg/m24, cyclophosphamide300mg/m24and
rabbitATG(thymoglobulin) 3.75mg/kg 4 (BMT2005; 36:947–50):
despite anoverall survival of 73%, rejectionwashigh inpatientsover 14
years of age (32%). For this reason, in patients over the age of 14 years,
we added total body irradiation (TBI 200) to this regimen and reduced
ATG to 3.75 mg/kg  2. Pediatric patients were allowed to continue
on the non-TBI regimen. We are now reporting 70 patients, of
whom 45 were grafted with FLU-CY and 25 with FLU-CY-
TBI200.The45FLU-CYpatients, include theoriginal 38.All patients
received ATG in the conditioning. The patients were grafted between
1998 and 2007.Themedian age for the FLU-CYof age was 13 and for
the FLU-CY-TBI itwas 29 (Table) .GvHDgrade III-IVwas seen in 1
patient in each groups. Rejection was seen in 13%of the first and 12%
of the second group. Rejection was the cause of death in 3 patients in
the FLU-CY group and in 2 patients in the FLU-CY-TBI group.
The overall crude survival (80%) was excellent in both groups: the ac-
tuarial 5 year survival is 79% and 77%. The median interval from di-
agnosis to transplant was 582 days for all patients: survival was 87%
vs 65% for patients grafted before or beyond that cut off. Causes of
death were rejection (5), PTLD (2), infections (5), hemorrhage (2).
These results suggest that alternative donor transplants can be safely
performed in patients with acquired aplastic anemia, also in adults.
The persisting risk of rejection may be due to the low dose of cyclo-
phosphamide (CY) which could be significantly increased.8
FAVORABLE LEUKEMIA-FREE SURVIVAL (LFS) FOR ADULTS AND
CHILDREN UNDERGOING MYELOABLATIVE UMBILICAL CORD BLOOD
(UCB) TRANSPLANTATION WITH CYCLOPHOSPHAMIDE (CY), FLUDARA-
BINE (FLU) AND TOTAL BODY IRRADIATION (TBI): A SINGLE CENTER
ANALYSIS OF 194 PATIENTS
Brunstein, C.G., Weisdorf, D.J., DeFor, T.E., Miller, J.S.,
McGlave, P.B., Blazar, B.R., Wagner, J.E. University of Minnesota,
Minneapolis, MN
Weevaluated the outcomes in 194 consecutive patients (pts) trans-
planted with UCB after a myeloablative therapy for acute myeloid
leukemia (AML, n 5 86), acute lymphoblastic leukemia (ALL, n 5
89), chronic myeloid leukemia (CML, n 5 13), and myelodysplastic
syndrome (MDS, n 5 6) between 1995 and 2007.
Methods: Pts were assigned to 3 treatment groups: Cy 120mg/kg,
TBI 1320 cGy and equine anti-thymocyte globulin (ATG) 90mg/kg
with one UCB unit (CyTBI, 1995–2000; n5 65; median age 9 yrs, r
0.5–52); CyTBI and Flu 75mg/m2/day with one UCB unit (CY-
FluTBI-1, 2000–2007; n 5 36; median age 8yrs, r 2–44); and Cy/
Flu/TBI with twoUCB units (CyFluTBI-2, 2001–2007; n5 93; me-
dian age 25yrs, r 9–45). All received cyclosporine A (CsA) with either
short course methylprednisolone or mycophenolate mofetil. Pts
were classified as standard (acute leukemia in CR1–2 or CML in first
chronic phase, n5 138) or high risk (n5 56) for relapse.Median fol-
low-up for survivors is 2.8 years (r: 0.7–9.2). Pts received a 0–1HLA-
mismatched graft in 81% for CyFluTBI-1, 47% for CyTBI, and
36% for CyFluTBI-2 (p\.01). The total nucleated cell dose infused
in recipients of CyFluTBI-1 was 3.6 (2.1–13.9), CyTBI 3.0
(0.9–14.0), and CyFluTBI-2 3.6 (1.7–6.5)  107/kg (p 5 .01).
Results: Engraftment was not significantly different for the 3
groups (CyFluTBI-1 97% (92–100) vs. CyTBI 89% (82–96) vs.CyFluTBI-2 87% (80–94) (p 5 .06). Incidence of grades II-IV
GVHD was higher after CyFluTBI-2 (51% [40–62]) as compared
to CyFluTBI-1 (25% [11–39]) or CyTBI 37% (25–49) (p\.01) in
univariate, but not in multivariate analysis after adjusting for age
and disease risk. While treatment-related mortality (TRM) at 2 yrs
was similar in univariate analysis (CyFluTBI-1, 11% [1–21] vs.
CyFluTBI-2, 32% [22–42] vs. CyTBI 32% [22–42], p 5 .07), after
adjusting for age and disease risk TRM was higher for the CyTBI
(RR 3.5 [1.1–9.2], p 5 .03) vs. CyFluTBI-1. The relapse risk at 4
yrs for CyFluTBI-1 was 37% (19–55), CyFluTBI-2 19% (10–28),
and CyTBI 28% (18–38) (p 5 .19). The LFS at 4 yrs for Cy-
FluTBI-1 was 52% (34–70), CyFluTBI-2 49% (38–60), and CyTBI
37% (25–49) (p5 .46). Inmultivariate analysis, only high risk disease
was associated with higher relapse risk (RR 2.0; 95%CI,1.0–3.9; p5
.05) and mortality (RR 2.2;95%CI,1.4–3.4; p\.01). Notably, cell
dose and HLA match had no effect on any outcome in multivariate
analysis. In conclusion, use of two partiallyHLAmatchedUCBunits
has increased the applicability ofUCBparticularly in adult recipients.9
EVALUATION OF RABBIT ANTITHYMOCYTE GLOBULIN (RATG) DOSE-
INTENSITY IN PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANS-
PLANTATION (ASCT) FOLLOWING REDUCED INTENSITY CONDITIONING
(RIC) WITH FLUDARABINE, BUSULFAN AND RATG (FBA)
Hamadani, M., Benson DM Jr., Jr., Porcu, P., Elder, P., Andritsos, L.,
Hofmeister, C.C., Krugh, D., Garzon, R., Lin, T., Marcucci, G.,
Blum,W., Devine, S.M. Arthur G. James Comprehensive Cancer Center,
the Ohio State University, Columbus, OH
We evaluated the effects of two doses of rATG (6.0 versus 7.5mg/
kg/total dose) in patients undergoing RIC. All patients (n5 54) were
conditioned with F (30mg/m2/day, days -7 to -3), B (0.8mg/kg/dose
IV  8 doses) and either 7.5mg/kg of rATG (7.5rA) (n 5 39) or
6.0mg/kg of rATG (6rA) (n 5 15), followed by micro-dose metho-
trexate and tacrolimus. Median age was 57 years. 76% (N 5 41)
had high-risk disease. 10 patients (18%) received mismatched allo-
grafts. 47 patients (87%) received grafts from unrelated donors. All
patients engrafted neutrophils and platelets promptly (median 15
and 17 days, respectively). One patient had secondary graft failure,
and another AML patient previously only treated with decitabine ex-
perienced secondary graft rejection. Both of these patients received
7.5rA. Compared to patients receiving 7.5rA, ones receiving 6rA
had fewer EBV (25% vs. 13%; p-value 5 0.3) CMV (61% vs.
25%; p-value5 0.05) and BK-viral (26% vs. 0%; p-value5 0.03) re-
activations and lower rates of relapse (33% vs. 6.6%; p-value5 0.04),
non-relapse mortality (28% vs. 0%; p-value 5 0.008), grade II-IV
acute GVHD (33% vs. 13%; p-value 5 0.1) and chronic GVHD
(45% vs. 13%; p-value5 0.03). None of the 6rA patients developed
PTLD. Chimerism analysis showed 100% donor CD331 chime-
rism at all time points and median donor CD31 chimerism of
94%, 97%, 99% and 100% at days 130, 160, 190 and 1180. No
difference was seen in the two rATG doses. 40 patients (74%)
were in CR after ASCT. The median follow-up of surviving patients
is 12 months (range 1–28 months). Compared to patients receiving
7.5rA, ones receiving 6rA showed trends toward improved 1-yr over-
all survival (63% vs. 100% p-value5 0.06) and progression free sur-
vival (47% vs. 91% p-value 5 0.06). Our preliminary data suggests
that 6rA promotes effective donor cell engraftment, without com-
promisingGVHDcontrol compared to 7.5rA, andmay be associated
with lower rates of infectious complications and disease relapse.
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GENOMIC INSTABILITY AFTER ALLOGENEIC HCT: FREQUENT IN ORAL
AND RARE IN NASAL MUCOSAL CELLS
Khan, F., Sy, S., Louie, P., Quinlan, D., Stewart, D., Russell, J.,
Storek, J. University of Calgary, Calgary, AB, Canada
Background: Genomic Instability (GI) is a precancerous or can-
cerous condition. Since oral carcinoma is frequent whereas nasal5
